Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 11/2001

01.09.2001 | Review Article

Intranasal Corticosteroids for Allergic Rhinitis

Superior Relief?

verfasst von: Dr Lars Peter Nielsen, Niels Mygind, Ronald Dahl

Erschienen in: Drugs | Ausgabe 11/2001

Einloggen, um Zugang zu erhalten

Abstract

Whether first-line pharmacological treatment of allergic rhinitis should be antihistamines or intranasal corticosteroids has been discussed for several years.
First-generation antihistamines are rarely used in the treatment of allergic rhinitis, mainly because of sedative and anticholinergic adverse effects. On the basis of clinical evidence of efficacy, no second-generation antihistamine seems preferable to another. Similarly, comparisons of topical and oral antihistamines have been unable to demonstrate superior efficacy for one method of administration over the other.
Current data documents no striking differences in efficacy and safety parameters between intranasal corticosteroids.
When the efficacy of antihistamines and intranasal corticosteroids are compared in patients with allergic rhinitis, present data favours intranasal corticosteroids. Interestingly, data do not show antihistamines as superior for the treatment of conjunctivitis. Safety data from comparative studies in patients with allergic rhinitis do not indicate differences between antihistamines and intranasal corticosteroids. Combining antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis does not provide any additional effect to intranasal corticosteroids alone. On the basis of current data, intranasal corticosteroids seem to offer superior relief in allergic rhinitis than antihistamines.
Literatur
1.
International Rhinitis Management Working Group. International consensus report on the diagnosis and management of rhinitis. Allergy 1994; 49: 5–34
2.
Sibbald B, Rink E, D’Souza M. Is the prevalence of atopy increasing? Br J Gen Pract 1990; 40: 338–40PubMed
3.
Aberg N, Sundell J, Eriksson B, et al. Prevalence of allergic diseases in school children in relation to family history, upper respiratory tract infections and residential characteristics. Allergy 1996; 5 1: 232–7PubMed
4.
Bousquet J, Bullinger M, Fayol C, et al. Assessment of the quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnairre. J Allergy Clin Immunol 1994; 94: 182–8PubMedCrossRef
5.
Juniper EF, Guyatt GH, Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 1994 Feb; 93: 413–23PubMedCrossRef
6.
Simons FE. Learning impairment and allergic rhinitis. Allergy Asthma Proc 1996 Jul; 17: 185–9PubMedCrossRef
7.
Spector SL. Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol 1997 Feb; 99: S773–S80PubMedCrossRef
8.
Mygind N. Local effect of intranasal beclomethasone dipropionate aerosol in hay fever. BMJ 1973 Nov 24; 4: 464–6PubMedCrossRef
9.
Holmberg K, Pipkorn U, Bake B, et al. Effects of topical treatment with H1 and H2 antagonists on clinical symptoms and nasal vascular reactions in patients with allergic rhinitis. Allergy 1989 May; 44: 281–7PubMedCrossRef
10.
Wang D, Clement P, Smitz J. Effect of H1 and H2 antagonists on nasal symptoms and mediator release in atopic patients after nasal allergen challenge during the pollen season. Acta Otolaryngol 1996 Jan; 116: 91–6PubMedCrossRef
11.
Andersson M, Nolte H, Baurngarten C, et al. Suppressive effect of loratadine on allergen-induced histamine release in the nose. Allergy 1991 Oct; 46: 540–6PubMedCrossRef
12.
Bousquet J, Lebel B, Chanal I, et al. Antiallergic activity of H1-receptor antagonists assessed by nasal challenge. J Allergy Clin Immunol 1988 Nov; 82: 881–7PubMedCrossRef
13.
Campbell A, Michel FB, Bremard-Oury C, et al. Overview of allergic mechanisms. Ebastine has more than an antihistamine effect. Drugs 1996; 52 Suppl. 1: 15–9
14.
Ciprandi G, Pronzato C, Ricca V, et al. Terfenadine exerts antiallergic activity reducing ICAM-1 expression on nasal epithelial cells in patients with pollen allergy. Clin Exp Allergy 1995 Sep; 25: 871–8PubMedCrossRef
15.
Ciprandi G, Buscaglia S, Pesce G, et al. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. J Allergy Clin Immunol 1995 Feb; 95: 612–21PubMedCrossRef
16.
Ciprandi G, Pronzato C, Ricca V, et al. Loratadine treatment of rhinitis due to pollen allergy reduces epithelial ICAM-1 expression. Clin Exp Allergy 1997 Oct; 27: 1175–83PubMedCrossRef
17.
Fade R, Herpin-Richard N, Rihoux JP, et al. Inhibitory effect of cetirizine 211C1 on eosinophil migration in vivo. Clin Allergy 1987 Jul; 17: 373–9CrossRef
18.
Naclerio RM, Kagey-Sobotka A, Lichtenstein LM, et al. Terfenadine, an H 1 antihistamine, inhibits histamine release in vivo in the human. Am Rev Respir Dis 1990 Jul; 142: 167–71PubMed
19.
Jacobi HH, Skov PS, Poulsen LK, et al. Histamine and tryptase in nasal lavage fluid after allergen challenge: effect of 1 week of pretreatment with intranasal azelastine or systemic cetirizine. J Allergy Clin Immunol 1999; 103: 768–72PubMedCrossRef
20.
Bronsky EA, Dockhom RJ, Meltzer EO, et al. Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1996 Apr; 97: 915–21PubMedCrossRef
21.
Klementsson H, Andersson M, Pipkorn U. Allergen-induced increase in nonspecific nasal reactivity is blocked by antihistamines without a clear-cut relationship to eosinophil influx. J Allergy Clin Inimunol 1990 Oct; 86: 466–72CrossRef
22.
Roquet A, Rand J, Hallden G, et al. Effect of loratadine on anti-IgE induced inflammation, histamine release and leucocyte recruitment in skin of atopics. Allergy 1995; 50: 414–20PubMedCrossRef
23.
Bentley AM, Walker S, Hanotte F, et al. A comparison of the effects of oral cetirizine and inhaled beclomethasone on early and late asthmatic responses to allergen and the associated increase in airways hyperresponsiveness. Clin Exp Allergy 1996; 26: 909–17PubMedCrossRef
24.
Brogden RN, McTavish D. Acrivastine: a review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and related disorders. Drugs 1991 Jun; 41: 927–40PubMedCrossRef
25.
Campoli-Richards DM, Buckley MM, Fitton A. Cetirizine. A review of its pharmacological properties and clinical potential in allergic rhinitis, pollen-induced asthma, and chronic urticaria. Drugs 1990 Nov; 40: 762–81
26.
Leynadier F, Bousquet J, Murrieta M, et al. Efficacy and safety of mizolastine in seasonal allergic rhinitis. The Rhinase Study Group. Ann Allergy Asthma Immunol 1996 Feb; 76: 163–8CrossRef
27.
Pelaez A. Clinical efficacy of ebastine in the treatment and prevention of seasonal allergic rhinitis. Drugs 1996; 52 Suppl. 1: 35–8PubMedCrossRef
28.
Richards DM, Brogden RN, Heel RC, et al. Asten-fizole: a review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1984 Jul; 28: 38–61PubMedCrossRef
29.
Simpson K, Jarvis B. Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 2000 Feb; 59(2): 301–21PubMedCrossRef
30.
Sorkin EM, Heel RC. Terfenadine: a review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1985 Jan; 29: 34–56PubMedCrossRef
31.
Haria M, Fitton A, Peters DH. Loratadine: a reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs 1994; 48: 617–37PubMedCrossRef
32.
Ciprandi G, Ricca V, Tosca M, et al. Continous antihistamine treatment controls allergic inflammation and reduces respiratory morbidity in children with mite allergy. Allergy 1999; 54: 358–65PubMedCrossRef
33.
ETAC-study-group. Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomized, placebo-controlled trial: first results of ETAC. Pediatr Allergy Immunol 1998; 9: 116–24CrossRef
34.
Simons FE, Simons M. The pharmacology and use of H 1 -receptor-antagonist drugs. N Engl J Med 1994; 330: 1663–70PubMedCrossRef
35.
Renwick AG. The metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes. Clin Exp Allergy 1999; 3: 116–24CrossRef
36.
Simons FE, Kesselman MS, Giddins NG, et al. Asternizole-induced torsade de pointes. Lancet 1988 Sep 10; II: 624CrossRef
37.
Barbey JT, Anderson M, Ciprandi G, et al. Cardiovascular safety of second-generation antihistamines. Am J Rhinol 1999; 13: 23 5–43CrossRef
38.
Crane JK, Shih HT. Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. Am J Med 1993; 95: 445–6PubMedCrossRef
39.
Rankin AC. Non-sedating antihistamines and cardiac arrhythmia. Lancet 1997 Oct 18; 350: 1115–6PubMedCrossRef
40.
Woosley RL, Sale M. QT interval: a measure of drug action. Am J Cardiol 1993; 72: 36B43BCrossRef
41.
van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000 Feb; 55(2): 116–34CrossRef
42.
Chervinsky P, Georgitis J, Banov C, et al. Once daily loratadine versus astemizole once daily. Ann Allergy 1994 Aug; 73: 109–13PubMed
43.
Wilil JA, Petersen BN, Petersen LN, et al. Effect of the non-sedative H I -receptor antagonist astemizole in perennial allergic and nonallergic rhinitis. J Allergy Clin Immunol 1985 Jun; 75: 720–7CrossRef
44.
Raemakers JG, O’Hanlon JF. Acrivastine, terfenadine and diphenhydramine effects on driving performance as a function of dose and time after dosing. Eur J Clin Pharmacol 1994; 47: 261–6CrossRef
45.
Falliers CJ, Brandon ML, Buchman E, et al. Double-blind comparison of cetirizine and placebo in the treatment of seasonal rhinitis. Ann Allergy 1991 Mar; 66: 257–62PubMed
46.
McNeely W, Wiseman LR. Intranasal azelastine. A review of its efficacy in the management of allergic rhinitis. Drugs 1998 Jul;56: 91–114
47.
Noble S, McTavish D. Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis. Drugs 1995 Dec; 50: 1032–49
48.
Rombaut N, Bliatti JZ, Curran S, et al. Effects of topical administration of levocabastine on psychomotor and cognitive function. Ann Allergy 1991; 67: 75–9PubMed
49.
Wang D, Clement P, Smitz J, et al. Ihe activity of recent antiallergic drugs in the treatment of seasonal allergic rhinitis. Acta Otorhinolaryngol Belg 1996; 50: 25–32PubMed
50.
Day JH, Briscoe MP, Clark RH, et al. Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis. Ann Allergy Asthma Immunol 1997 Aug; 79: 163–72PubMedCrossRef
51.
Frossard N, Lacronique J, Melac M, et al. Onset of action in the nasal antihistaminic effect of cetirizine and loratadine in patients with allergic rhinitis. Allergy 1997 Feb; 52: 205–9PubMedCrossRef
52.
Meltzer EO, Weiler JM, Widlitz MD. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J Allergy Clin Immunol 1996 Feb; 97: 617–26PubMedCrossRef
53.
Frossard N, Benabdesselam 0, Melac M, et al. Nasal effect of cetirizine and loratadine at 24 hours in patients with allergic rhinitis. Am J Ther 1998 Sep; 5: 307–11PubMedCrossRef
54.
Terrien MH, Rahm F, Fellrath JM, et al. Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen. J Allergy Clin Immunol 1999 Jun; 103: 1025–30PubMedCrossRef
55.
al-Muhaimeed H. A parallel-group comparison of astemizole and loratadine for the treatment of perennial allergic rhinitis. J Int Med Res 1997 Jul; 25: 175–81PubMed
56.
Lobaton P, Moreno F, Coulie P. Comparison of cetirizine with astemizole in the treatment of perennial allergic rhinitis and study of the concomitant effect on histamine and allergen-induced wheal responses. Ann Allergy 1990 Nov; 65: 401–5PubMed
57.
Murris-Espin M, Melac M, Charpentier JC, et al. Comparison of efficacy and safety of cetirizine and ebastine in patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol 1998 May; 80: 399–403PubMedCrossRef
58.
Renton P, Fidler C, Rosenberg R. Multicenter, crossover study of the efficacy and tolerability of terfenadine, 120 mg, versus cetirizine, 10 mg, in perennial allergic rhinitis. Ann Allergy 1991 Oct: 416–20
59.
Bellioni P, Catalano B, Cervellera G, et al. Comparison of mizolastine with loratadine in the treatment of perennial allergic rhinitis. Rhinology 1996 Jun; 34: 101–4PubMed
60.
Carlsen KH, Kramer J, Fagertun HE, et al. Loratadine and terfenadine in perennial allergic rhinitis. Treatment of non-responders to the one drug with the other drug. Allergy 1993 Aug; 48: 431–6
61.
Day JH, Briscoe M, Widlitz MD. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. J Allergy Clin Immunol 1998 May; 10 1: 63 8–45
62.
Persi L, Demoly P, Harris AG, et al. Comparison between nasal provocation tests and skin tests in patients treated with loratadine and cetirizine. J Allergy Clin Immunol 1999 Apr; 103: 591–4PubMedCrossRef
63.
Gervais P, Bruttinan G, Pedrali P, et al. French multicentre double-blind study to evaluate the efficacy and safety of acrivastine as compared with terfenadine in seasonal allergic rhinitis. J Int Med Res 1989; 17 Suppl. 2: 47B–53BPubMed
64.
Harcup JW, Hawkes G, Saul PA. The efficacy and sedative profile of astemizole and cetirizine in the treatment of grass pollen hayfever in general practice. Br J Clin Pract 1993 May; 47: 131–5PubMed
65.
Bonifazi F, Provinciali L, Antonicelli L, et al. Comparative study of terfenadine and cetirizine in hay fever: assessment of efficacy and central nervous system effects. J Investig Al-lergol Clin Immunol 1995 Jan; 5: 40–6
66.
Caiaffa MF, ludice A, Macchia L, et al. Multicenter double-blind comparative study of terfenadine and cetirizine in hay fever. J Invest Allergol Clin Immunol 1992 May; 2: 162–6
67.
Gehanno P, Bremard-Oury C, Zeisser P. Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults. Ann Allergy Asthma Immunol 1996 Jun; 76: 507–12PubMedCrossRef
68.
Howarth PH, Stem NIA, Roi L, et al. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 ing once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999 Nov; 104: 927–33PubMedCrossRef
69.
Sabbah A, Daele J, Wade AG, et al. Comparison of the efficacy, safety, and onset of action of niizolastine, cetirizine, and placebo in the management of seasonal allergic rhinoconjunctivitis. MIZOCET Study Group. Ann Allergy Asthma Immunol 1999 Oct; 83: 319–25CrossRef
70.
Olsen OT, Nuchel PL, Hoi L, et al. Comparison of loratadine and terfenadine in allergic seasonal rhinoconjunctivitis with emphasis on nasal stuffiness and peak flow. Arzneimittelforschung 1992 Oct; 42: 1227–31PubMed
71.
Berkowitz RB, Dockhom R, Lockey P, et al. Comparison of efficacy, safety, and skin test inhibition of cetirizine and astenlizole. Ann Allergy Asthma Immunol 1996 Apr; 76: 363–8PubMedCrossRef
72.
Cohen B, Gehanno P. Comparison of the efficacy of ebastine 10ing and 20ing once daily with that of cetirizine 10ing once daily in adults with seasonal allergic rhinitis: a multicentre double-blind study. Drugs 1996; 52 Suppl. 1: 26–9: 26–9PubMedCrossRef
73.
Lockey RF, Widlitz MD, Mitchell DQ, et al. Comparative study of cetirizine and terfenadine versus placebo in the symptomatic management of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1996 May; 76: 448–54PubMedCrossRef
74.
Baroody FM, Lim MC, Proud D, et al. Effects of loratadine and terfenadine on the induced nasal allergic reaction. Arch Otolaryngol Head Neck Surg 1996 Mar; 122: 309–16PubMedCrossRef
75.
Boner AL, Richelli C, Castellani C, et al. Comparison of the effects of loratadine and astemizole in the treatment of children with seasonal allergic rhinoconjunctivitis. Allergy 1992 Apr; 47: 98–102PubMedCrossRef
76.
Sienra-Monge JJ, Gazca-Aguilar A, Del Rio-Navarro B. Double-blind comparison of cetirizine and loratadine in children ages 2 to 6 years with perennial allergic rhinitis. Am J’ffier 1999 May; 6: 149–55
77.
Charpin D, Godard P, Garay RP, et al. A multicenter clinical study of the efficacy and tolerability of azelastine nasal spray in the treatment of seasonal allergic rhinitis: a comparison with oral cetirizine. Eur Arch Otorhinolaryngol 1995; 252: 455–8PubMedCrossRef
78.
Passali D, Piragine F. A comparison of azelastine nasal spray and cefirizine tablets in the treatment of allergic rhinitis. J Int Med Res 1994 Jan; 22: 17–23PubMed
79.
Conde HD, Palma AJ, Delgado RJ. Comparison of azelastine nasal spray and oral ebastine in treating seasonal allergic rhinitis. Curr Med Res Opin 1995; 13: 299–304CrossRef
80.
Gambardella R. A comparison of the efficacy of azelastine nasal spray and loratidine tablets in the treatment of seasonal allergic rhinitis. J Int Med Res 1993 Sep; 21: 268–75PubMed
81.
Gastpar H, Nolte D, Aurich R, et al. Comparative efficacy of azelastine nasal spray and terfenadine in seasonal and perennial rhinitis. Allergy 1994 Mar; 49: 152–8PubMedCrossRef
82.
Bahmer FA, Ruprecht KW. Safety and efficacy of topical levocabastine compared with oral terfenadine. Ann Allergy 1994 May; 72: 429–34PubMed
83.
Sohoel P, Freng B A, Kramer J, et al. Topical levocabastine compared with orally administered terfenadine for the prophylaxis and treatment of seasonal rhinoconjunctivitis. J Allergy Clin Immunol 1993 Jul; 92: 73–81PubMedCrossRef
84.
The Livostin Study Group. A comparison of topical levocabastine and oral terfenadine in the treatment of allergic rhino-conjunctivitis. Allergy 1993 Oct; 48: 530–4CrossRef
85.
Swedish GP Allergy Team. Topical levocabastine compared with oral loratadine for the treatment of seasonal allergic rhinoconjunctivitis. Allergy 1994 Sep; 49: 611–5CrossRef
86.
Mygind N, Lund V. Topical corticosteroid therapy of rhinitis. Clin Immunother 1996; 5: 122–36CrossRef
87.
88.
Cato AC, Wade E. Molecular mechanisms of antfinflammatory action of glucocorticoids. Bioessays 1996; 18: 371–8PubMedCrossRef
89.
Godthelp T, Holm AF, Blom H, et al. The effect of fluticasone propionate aqueous nasal spray on nasal mucosal inflammation in perennial allergic rhinitis. Allergy 1995; 50: 21–4PubMedCrossRef
90.
Holm AF, Fokkens WJ, Godthelp T, et al. Effect of 3 months’ nasal steroid therapy on nasal T cells and Langerhans cells in patients suffering from allergic rhinitis. Allergy 1995 Mar; 50: 204–9PubMedCrossRef
91.
Holt PG, Thomas JA. Steroids inhibit uptake and/or processing but not presentation of antigen by airway dendritic cells. Immunology 1997; 91: 145–50PubMedCrossRef
92.
Gomez E, Clague JE, Gatland D, et al. Effect of topical corti-costeroids on seasonally induced increases in nasal mast cells. BMJ 1988 Jun 4; 296: 1572–3PubMedCrossRef
93.
Pipkorn U, Enerback L. Nasal mucosal mast cells and histamine in hay fever. Effect of topical glucocorticoid treatment. Int Arch Allergy Appl Immunol 1987; 84: 123–8CrossRef
94.
Bascom R, Wachs M, Naclerio R, et al. Basophil influx occurs after nasal antigen challenge: effects of topical corticosteroid pretreatment. J Allergy Clin Immunol 1988; 81: 580–9PubMedCrossRef
95.
Pipkorn U, Proud D, Lichtenstein LM, et al. Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids. N Engl J Med 1987 Jun 1 1; 316: 1506–10PubMedCrossRef
96.
Nielsen LP, Bjerke T, Christensen NW, et al. Eosinophil markers in seasonal allergic rhinitis. Intranasal fluticasone propionate inhibits local and systemic increases during the pollen season. Allergy 1998 Aug; 53: 778–85
97.
Schleimer RP, Bochner BS. The effects of glucocorticoids on human eosinophils. J Allergy Clin Immunol 1994; 94: 1202–13PubMedCrossRef
98.
Rolfe FG, Hughes JM, Armour CL, et al. Inhibition of interleu-kin-5 gene expression by dexamethasone. Immunology 1992; 77: 494–9PubMed
99.
Robinson D, Hamid Q, Ying S, et al. Prednisolone treatment in asthma is associated with modulation of bronchoalveolar lavage cell interleukin-4, interleukin-5 and interferon-gamma cytokine gene expression. Am Rev Respir Dis 1993; 148: 401–6PubMed
100.
Weido AJ, Reece LM, Alarn R, et al. Intranasal fluticasone propionate inhibits recovery of chemokines and other cytokines in nasal secretions in allergen-induced rhinitis. Ann Allergy Asthma Immunol 1996 Nov; 77: 407–15PubMedCrossRef
101.
Rak S, Jacobson MR, Sudderick RM, et al. Influence of prolonged treatment with topical corticosteroid (fluticasone propionate) on early and late phase nasal responses and cellular infiltration in the nasal mucosa after allergen challenge. Clin Exp Allergy 1994 Oct; 24: 930–9PubMedCrossRef
102.
Naclerio RM, Adkinson NFJ, Creticos PS, et al. Intranasal steroids inhibit seasonal increases in ragweedspecific immuno-globulin E antibodies. J Allergy Clin Immunol 1993 Nov; 92: 717–21PubMedCrossRef
103.
Pullerits T, Praks L, Sjostrand M, et al. An intranasal glucocorticoid inhibits the increase of specific IgE initiated during birch pollen season. J Allergy Clin Immunol 1997 Nov; 100: 601–5PubMedCrossRef
104.
Edwards TB. Effectiveness and safety of beclomethasone dipropionate, an intranasal corticosteroid, in the treatment of patients with allergic rhinitis. Clin Ther 1995 Nov; 17: 1032–41PubMedCrossRef
105.
Brogden RN, McTavish D. Budesonide. An updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis. Drugs 1992; 44: 375–407
106.
Pakes GE, Brogden RN, Heel RD, et al. Flunisolide: a review of its pharmacological properties and therapeutic efficacy in rhinitis. Drugs 1980 Jun; 19: 397–411PubMedCrossRef
107.
Wiseman LR, Benfield P. Intranasal fluticasone propionate. A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis. Drugs 1997; 53: 885–907
108.
Onrust SV, Lamb HM. Mometasone furoate. A review of its intranasal use in allergic rhinitis. Drugs 1998 Oct; 56: 725–45
109.
Jeal W, Faulds D. Trianicinolone acetonide. Areview of its pharmacological properties and therapeutic efficacy in the management of allergic rhinifis. Drugs 1997 Feb; 53: 257–80
110.
Aubier M, Levy J, Clerici C, et al. Different effects of nasal and bronchial glucocorticosteroid administration on bronchial hyperresponsiveness in patients with allergic rhinitis. Am Rev Respir Dis 1992 Jul; 146: 122–6PubMed
111.
Corren J, Adinoff AD, Buchmeier AD, et al. Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma. J Allergy Clin Immunol 1992 Aug; 90: 250–6PubMedCrossRef
112.
Foresi A, Pelucchi A, Gherson G, et al. Once daily intranasal fluticasone propionate (200 micrograms) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. J Allergy Clin Immunol 1996 Aug; 98: 274–82PubMedCrossRef
113.
Reed CE, Marcoux JP, Welsh PW Effects of topical nasal treatment on asthma symptoms. J Allergy Clin Immunol 1988 May; 81: 1042–7PubMedCrossRef
114.
Wood RA, Eggleston PA. The effects of intranasal steroids on nasal and pulmonary responses to cat exposure. Am J Respir Crit Care Med 1995 Feb; 151: 315–20PubMed
115.
Henriksen J, Wenzel A. Effects of intranasally adn-finistered corticosteroid (budesonide) on nasal obstruction, mouth breathing and asthma. Am Rev Respir Dis 1984; 130: 1014–8PubMed
116.
Berkowitz RB, Bernstein DI, LaForce C, et al. Onset of action of mometasone faroate nasal spray (NASONEX) in seasonal allergic rhinitis. Allergy 1999 Jan; 54: 64–9PubMedCrossRef
117.
Lumry WR. A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis. J Allergy Clin Immunol 1999 Oct; 104(4 Pt 1): S150–8PubMedCrossRef
118.
Sclner JC, Weber RW, Richmond GW, et al. Onset of action of aqueous beclomethasone dipropionate nasal spray in seasonal allergic rhinitis. Clin Ther 1995 Nov; 17: 1099–109CrossRef
119.
Day JH, Briscoe MP, Rafeiro E, et al. Onset of action of intranasal budesonide (Rhinocort aqua) in seasonal allergic rhinitis studied in a controlled exposure model. J Allergy Clin Immunol 2000 Mar; 105(3): 489–94PubMedCrossRef
120.
Holm AF, Fokkens WJ, Godthelp T, et al. A1 -year placebo-controlled study of intranasal fluticasone propionate aqueous nasal spray in patients with perennial allergic rhinitis: a safety and biopsy study. Clin Otolaryngol 1998 Feb; 23: 69–73PubMedCrossRef
121.
Banov CH, Woeffier TB, LaForce CF, et al. Once daily intranasal fluticasone propionate is effective for perennial allergic rhinitis. Ann Allergy 1994 Sep; 73: 240–6PubMed
122.
Bliatia M, Campbell LM, Ross JR, et al. Intranasal budesonide once daily in seasonal allergic rhinitis. Curr Med Res Opin 1999 1; 12: 287–95
123.
Drouin M, Yang WH, Bertrand B, et al. Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients. Ann Allergy Asthma Immunol 1996 Aug; 77: 15 3–60CrossRef
124.
Munch E, Gomez G, Harris C, et al. An open comparison of dosage frequencies of beclomethasone dipropionate in seasonal allergic rhinitis. Clin Allergy 1981 May; 11: 303–9PubMedCrossRef
125.
Nathan RA, Bronsky EA, Fireman P, et al. Once daily fluticasone propionate aqueous nasal spray is an effective treatment for seasonal allergic rhinitis. Ann Allergy 1991 Sep; 67: 332–8PubMed
126.
Dolovich J, O’Connor M, Stepner N, et al. Double-blind comparison of intranasal fluticasone propionate, 200 micrograms, once daily with 200 micrograms twice daily in the treatment of patients with severe seasonal allergic rhinitis to ragweed. Ann Allergy 1994 May; 72: 435–40PubMed
127.
Toft A, Wihl JA, Toxman J, et al. Double-blind comparison between beclomethasone dipropionate as aerosol and as powder in patients with nasal polyposis. Clin Allergy 1982 Jul; 12: 391–401PubMedCrossRef
128.
Andersson M, Berglund R, Greiff L, et al. A comparison of budesonide nasal dry powder with fluticasone propionate aqueous nasal spray in patients with perennial allergic rhinitis. Rhinology 1995 Mar; 33: 18–21PubMed
129.
LaForee C. Use of nasal steroids in managing allergic rhinitis. J Allergy Clin Immunol 1999 Mar; 103: S388–S94CrossRef
130.
Cervin A, Andersson M. Intranasal steroids and septum perforation — an overlooked complication? A description of the course of events and a discussion of the causes. Rhinology 1998 Sep; 36: 12832
131.
Soderberg-Warner ML. Nasal septal perforation associated with topical corticosteroid therapy. J Pediatr 1984 Nov; 105: 840–1PubMedCrossRef
132.
Pipkorn U, Pukander J, Suonpaa J, et al. Long-term safety of budesonide nasal aerosol: a 5.5-year follow-up study. Clin Allergy 1988 May; 18: 253–9PubMedCrossRef
133.
Brown HM, Storey G, Jackson FA. Beclomethasone dipropionate aerosol in treatment of perennial and seasonal rhinitis: a review of five years’ experience. Br J Clin Pharmacol 1977; 4: 283–6CrossRef
134.
Holm AF, Godthelp T, Fokkens WJ, et al. Long-term effects of corticosteroid nasal spray on nasal inflammatory cells in patients with perennial allergic rhinitis. Clin Exp Allergy 1999 Oct; 29: 1356–66PubMedCrossRef
135.
Howland WC. Fluticasone propionate: topical or systemic effects? Clin Exp Allergy 1996 May; Suppl. 3: 18–22
136.
Vargas R, Dockhom RJ, Findlay SR, et al. Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the hypothalamic-pituitary-adrenal axis. J Allergy Clin Immunol 1998 Aug; 102: 191–7PubMedCrossRef
137.
Wilson AM, Sims W, McFarlane LC, et al. Effects of intranasal corticosteroids, on adrenal, bone, and blood markers of systemic activity in allergic rhinitis. J Allergy Clin Immunol 1998 Oct; 102: 598–604PubMedCrossRef
138.
Wolthers OD, Pedersen S. Knemometric assessment of systemic activity of once daily intranasal drypowder budesonide in children. Allergy 1994 Feb; 49: 96–9PubMedCrossRef
139.
Skoner D, Rachelefsky G, Meltzer E, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 2000; 105: e23PubMedCrossRef
140.
Agertoft L, Pedersen S. Short-term lower leg growth rate in children with rhinitis treated with intranasal mometasone furoate and budesonide. J Allergy Clin Immunol 1999 Nov; 104: 948–52PubMedCrossRef
141.
Passalacqua G, Albano M, Canonica GW, et al. Inhaled and nasal corticosteroids: safety aspects. Allergy 2000; 55: 16–33PubMedCrossRef
142.
Scadding GK, Lund VJ, Jacques LA, et al. A placebo-controlled study of fluticasone propionate aqueous nasal spray and beclomethasone dipropionate in perennial rhinitis: efficacy in allergic and nonallergic perennial rhinitis. Clin Exp Allergy 1995 Aug; 25: 737–43PubMedCrossRef
143.
van As A, Bronsky EA, Dockhom RJ, et al. Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone diproprionate. J Allergy Clin Inirminol 1993 Jun; 91: 1146–54CrossRef
144.
Mandl M, Nolop K, Lutsky BN. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. 194-79 Study Group. Ann Allergy Asthma Immunol 1997 Oct; 79: 370–8CrossRef
145.
Haye R, Gomez EG. A multicentre study to assess long-term use of fluticasone propionate aqueous nasal spray in comparison with beclomethasone dipropionate aqueous nasal spray in the treatment of perennial rhinitis. Rhinology 1993 Dec; 31: 169–74PubMed
146.
Svendsen UG, Frolund L, Madsen F, et al. Beclomethasone dipropionate versus flunisolide as topical steroid treatment in patients with perennial rhinitis. Clin Otolaryngol 1989 Oct; 14: 441–5PubMedCrossRef
147.
al-Mohaimeid H. A parallel-group comparison of budesonide and beclomethasone dipropionate for the treatment of perennial allergic rhinitis in adults. J Int Med Res 1993 Mar; 21: 67–77PubMed
148.
Adamopoulos G, Manolopoulos L, Giotakis I. Acomparison of the efficacy and patient acceptability of budesonide and beclomethasone dipropionate aqueous nasal sprays in patients with perennial rhinitis. Clin Otolaryngol 1995 Aug; 20: 340–4PubMedCrossRef
149.
Day J, Carrillo T. Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis. J Allergy Clin Immunol 1998 Dec; 102: 902–8PubMedCrossRef
150.
McAllen MK, Portillo PR, Parr EJ, et al. Intranasal flunisolide, placebo and beclomethasone dipropionate in perennial rhinitis. Br J Dis Chest 1980 Jan; 74: 32–6PubMedCrossRef
151.
Sahay JN, Chatterjee SS, Engler C. A comparative trial of flunisolide and beclomethasone dipropionate in the treatment of perennial allergic rhinitis. Clin Allergy 1980 Jan; 10: 65–70PubMedCrossRef
152.
Graft D, Aaronson D, Chervinsky P, et al. A placebo- and active-controlled randon-tized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray. J Allergy Clin Immunol 1996 Oct; 98: 724–31PubMedCrossRef
153.
Hebert JP, Nolop K, Lutsky BN. Once-daily mometasone furoate aqueous nasal spray (Nasonex) in seasonal allergic rhinitis: an active- and placebo-controlled study. Allergy 1996 Aug; 51: 569–76PubMed
154.
Ratner PH, Pauli BR, Findlay SR, et al. Fluticasone propionate given once daily is as effective for seasonal allergic rhinitis as beclomethasone dipropionate given twice daily. J Allergy Clin Immunol 1992 Sep; 90: 285–91PubMedCrossRef
155.
Vanzieleghern NIA, Juniper EF. A comparison of budesonide and beclomethasone dipropionate nasal aerosols in ragweed-induced rhinitis. J Allergy Clin Immunol 1987 Jun; 79: 887–92CrossRef
156.
Sipila P, Sorri M, Ojala K, et al. Comparative trial of flunisolide and beclomethasone dipropionate nasal sprays inpatients with seasonal allergic rhinitis. Allergy 1983 Jul; 38: 303–7PubMedCrossRef
157.
Aasand G, Etholm BO, Skjostad M, et al. Flunisolide nasal spray compared to beclomethasone dipropionate in the treatment of seasonal rhinitis. Rhinology 1982 Dec; 20: 205–11PubMed
158.
Langrick AR Comparison of flunisolide and beclomethasone dipropionate in seasonal allergic rhinitis. Curr Med Res Opin 1984; 9: 290–5PubMedCrossRef
159.
Pipkorn U, Geterud A. A comparative trial testing budesonide and flunisolide nasal sprays in patients with seasonal allergic rhinitis. Arm Allergy 1984 Mar; 52: 183–6
160.
Small P, Houle PA, Day JH, et al. Acomparison of triamcinolone acetonide nasal aerosol spray and fluticasone propionate aqueous solution spray in the treatment of spring allergic rhinitis. J Allergy Clin Immunol 1997 Nov; 100: 592–5PubMedCrossRef
161.
Pipkorn U. Hay fever treatment with budesonide and beclomethasone dipropionate twice daily — a clinical comparison. Rhinology 1983 Dec; 21: 335–40PubMed
162.
McArthur JG. Acomparison of budesonide and beclomethasone dipropionate sprays in the treatment of seasonal allergic rhinitis. Clin Otolaryngol 1994 Dec; 19: 537–42PubMedCrossRef
163.
Stem MA, Dahl P, Nielsen LP, et al. A comparison of aqueous suspensions of budesonide nasal spray (128 micrograms and 256 micrograms once daily) and fluticasone propionate nasal spray (200 micrograms once daily) in the treatment of adult patients with seasonal allergic rhinitis. Am J Rhinol 1997 Jul; 11: 323–30CrossRef
164.
Robinson AC, Cherry JR, Daly S. Double-blind cross-over trial comparing beclomethasone dipropionate and terfenadine in perennial rhinitis. Clin Exp Allergy 1989 Sep; 19: 569–73PubMedCrossRef
165.
Bunnag Q Jareoncharsri P, Wong EC. A double-blind comparison of nasal budesonide and oral astemizole for the treatment of perennial rhinitis. Allergy 1992 Aug; 47: 313–7PubMedCrossRef
166.
Sibbald B, Hilton S, D’Souza M. An open cross-over trial comparing two doses of astemizole and beclomethasone dipropionate in the treatment of perennial rhinitis. Clin Allergy 1986 May; 16: 203–11PubMedCrossRef
167.
Davies RJ, Lund VJ, Harten-Ash VJ. The effect of intranasal azelastine and beclomethasone on the symptoms and signs of nasal allergy in patients with perennial allergic rhinitis. Rhinology 1993 Dec; 31: 159–64PubMed
168.
Stern MA, Wade AG, Ridout SM, et al. Nasal budesonide offers superior symptom relief in perennial allergic rhinitis in comparison to nasal azelastine. Ann Allergy Asthma Immunol 1998 Oct; 8 1: 354–8PubMedCrossRef
169.
van de Heyning PH, van HJ, Creten W, et al. Effect of topical levocabastine on allergic and non-allergic perennial rhinitis. A double-blind study, levocabastine vs. placebo, followed by an open, prospective, single-blind study on beclomethasone. Allergy 1988 Jul; 43: 386–91
170.
Beswick KB, Kenyon GS, Cherry JR. A comparative study of beclomethasone dipropionate aqueous nasal spray with terfenadine tablets in seasonal allergic rhinitis. Curr Med Res Opin 1985; 9: 5607CrossRef
171.
Lancer JM, Jones AS, Stevens JC, et al. A comparison by rhinomanometry of beclomethasone and terfenadine in the treatment of seasonal rhinitis. J Laryngol Otol 1987; 10 1: 350–4CrossRef
172.
Darnell R, Pecoud A, Richards DH. A double-blind comparison of fluticasone propionate aqueous nasal spray, terfenadine tablets and placebo in the treatment of patients with seasonal allergic rhinitis to grass pollen. Clin Exp Allergy 1994 Dec; 24: 1144–50PubMed
173.
van Bavel J, Findlay SR, Hampel FCJ, et al. Intranasal fluticasone propionate is more effective than terfenadine tablets for seasonal allergic rhinitis. Arch Intern Med 1994 Dec 12; 154: 2699–704PubMedCrossRef
174.
Frolund L. Efficacy of an oral antihistamine, loratadine, as compared with a nasal steroid spray, beclomethasone dipropionate, in seasonal allergic rhinitis. Clin Otolaryngol 1991 Dec; 16: 527–31PubMedCrossRef
175.
Condemi J, Schulz R, Lim J. Triamcinolone acetonide aqueous nasal spray versus loratadine in seasonal allergic rhinitis: efficacy and quality of life. Ann Allergy Asthma Immunol 2000 May; 84: 533–8PubMedCrossRef
176.
Schoenwetter W, Lim J. Comparison of intranasal triaincinolone acetonide with oral loratadine for the treatment of patients with seasonal allergic rhinitis. Clin Ther 1995 May; 17: 479–92PubMedCrossRef
177.
Gehanno P, Desfougeres JL. Fluticasone propionate aqueous nasal spray compared with oral loratadine in patients with seasonal allergic rhinitis. Allergy 1997 Apr; 52: 445–50PubMedCrossRef
178.
Jordana G, Dolovich J, Briscoe MP, et al. Intranasal fluticasone propionate versus loratadine in the treatment of adolescent patients with seasonal allergic rhinitis. J Allergy Clin Immunol 1996 Feb; 97: 588–95PubMedCrossRef
179.
Salomonsson P, Gottberg L, Heilbom H, et al. Efficacy of an oral antihistamine, astemizole, as compared to a nasal steroid spray in hay fever. Allergy 1988 Apr; 43: 214–8PubMedCrossRef
180.
Wood SF. Oral antihistamine or nasal steroid in hay fever: a double-blind double-dummy comparative study of once daily oral astemizole vs twice daily nasal beclomethasone dipropionate. Clin Allergy 1986 May; 16: 195–201PubMedCrossRef
181.
Bernstein DI, Creticos PS, Busse WW, et al. Comparison of triamcinolone acetonide nasal inhaler with astemizole in the treatment of ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1996 Mar; 97: 749–55PubMedCrossRef
182.
Vervloet D, Charpin D, Desfougeres X. Intranasal fluticasone once daily compared with once daily cetirizine in the treatment of seasonal allergic rhinitis. Clin Drug Invest 1997; 13: 291–8CrossRef
183.
Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomized controlled trials. BMJ 1998 Dec 12; 317: 1624-PubMedCrossRef
184.
Newson-Smith G, Powell M, Baelire M, et al. A placebo controlled study comparing the efficacy of intranasal azelastine and beclomethasone in the treatment of seasonal allergic rhinitis. Eur Arch Otorhinolaryngol 1997; 254: 236–41PubMedCrossRef
185.
Pelucchi A, Chiapparino A, Mastropasqua B, et al. Effect of intranasal azelastine and beclomethasone dipropionate on nasal symptoms, nasal cytology, and bronchial responsiveness to methacholine in allergic rhinitis in response to grass pollens. J Allergy Clin Immunol 1995 Feb; 95: 515–23PubMedCrossRef
186.
Dorow P, Aurich R, Petzold U. Efficacy and tolerability of azelastine nasal spray in patients with allergic rhinitis compared to placebo and budesonide. Arzneinlittelforschung 1993 Aug; 43: 909–12
187.
Wang D, Smitz J, De Waele M, et al. Effect of topical applications of budesonide and azelastine on nasal symptoms, eosinophil count and mediator release in atopic patients after nasal allergen challenge during the pollen season. Int Arch Allergy Immunol 1997 Oct; 114: 185–92PubMedCrossRef
188.
Svensson C, Andersson M, Greiff L, et al. Effects of topical budesonide and levocabastine on nasal symptoms and plasma exudation responses in seasonal allergic rhinitis. Allergy 1998 Apr; 53: 367–74PubMedCrossRef
189.
Di Lorenzo G, Gervasi F, Drago A, et al. Comparison of the effects of fluticasone propionate, aqueous nasal spray and levocabastine on inflammatory cells in nasal lavage and clinical activity during the pollen season in seasonal rhinitics. Clin Exp Allergy 1999 Oct; 29: 1367–77PubMedCrossRef
190.
Ortolani C, Foresi A, Di Lorenzo G, et al. A double-blind, placebo-controlled comparison of treatment with fluticasone propionate and levocabastine in patients with seasonal allergic rhinitis. FLNC02 Italian Study Group. Allergy 1999 Nov; 54: 1173–80
191.
Juniper EF, Kline PA, Hargreave FE, et al. Comparison of beclomethasone dipropionate aqueous nasal spray, astemizole, and the combination in the prophylactic treatment of ragweed pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 1989 Mar; 83: 627–33PubMedCrossRef
192.
Ratner PH, van Bavel J, Martin BG, et al. A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis. J Fam Pract 1998 Aug; 47: 118–25PubMed
193.
Simpson RJ. Budesonide and terfenadine, separately and in combination, in the treatment of hay fever. Ann Allergy 1994 Dec; 73: 497–502PubMed
194.
Brooks CD, Francom SF, Peel BG, et al. Spectrum of seasonal allergic rhinitis symptom relief with topical corticoid and oral antihistamine given singly or in combination. Am J Rhinol 1996; 10: 193–9CrossRef
195.
Backhouse Cl, Finnamore VP, Gosden CW. Treatment of seasonal allergic rhinitis with flunisolide and terfenadine. J Int Med Res 1986; 14: 35–41PubMed
196.
Juniper EF, Guyatt GH, Ferrie PJ, et al. First-line treatment of seasonal (ragweed) rhinoconjunctivitis. A randomized management trial comparing a nasal steroid spray and a nonsedating antihistamine. CMAJ 1997 Apr 15; 156: 1123–31
197.
Kozma CM, Schulz RM, Sclar DA, et al. A comparison of costs and efficacy of intranasal fluticasone propionate and terfenadine tablets for seasonal allergic rhinitis. Clin Ther 1996 Mar; 18: 334–46PubMedCrossRef
198.
Berka C, Chin W. Fluticasone propionate intranasal steroid: cost-effectiveness vs antihistamines. J Allergy Clin Immunol 1994; 93: 165
199.
Slater JW, Zechnich AD, Haxby DG. Second-generation antihistamines: a comparative review. Drugs 1999 Jan; 57: 31–47PubMedCrossRef
200.
Dykewicz MS, Fineman S. Executive summary of Joint Task Force Practice Parameters on Diagnosis and Management of Rhinitis. Ann Allergy Asthma Immunol 1998; 81: 463–8PubMedCrossRef
Metadaten
Titel
Intranasal Corticosteroids for Allergic Rhinitis
Superior Relief?
verfasst von
Dr Lars Peter Nielsen
Niels Mygind
Ronald Dahl
Publikationsdatum
01.09.2001
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 11/2001
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200161110-00004

Weitere Artikel der Ausgabe 11/2001

Drugs 11/2001 Zur Ausgabe

Leading Article

Recent Advances in the Treatment of Gastric Cancer

Current Opinion

Should Inhaled Corticosteroids be Used in the Long Term Treatment of Chronic Obstructive Pulmonary Disease?

Adis Drug Evaluation

Repaglinide

Adis Drug Evaluation

Interferon Alfacon-1

Therapy in Practice

Optimising Outcomes in Acute Pancreatitis

Leading Article

Anti-Emetics for Cancer Chemotherapy-Induced Emesis Potential of Alternative Delivery Systems